|23rd February 2021||Frederick W Driscoll||25,000||Open or private sale||$4.03||$100,625.00|
|5th February 2021||Richard Adcock||150,000||Exercise of derivative||$0.00|
|5th February 2021||Barry J. Simon||22,100||Exercise of derivative||$2.00||$44,164.64|
|5th February 2021||Richard Adcock||68,171||Payment by withholding||$23.72||$1,617,016.12|
|5th February 2021||Barry J. Simon||22,100||Open or private sale||$23.09||$510,266.90|
|2nd February 2021||Barry J. Simon||82,070||Open or private sale||$20.65||$1,694,802.95|
|2nd February 2021||Barry J. Simon||82,070||Exercise of derivative||$2.00||$164,008.69|
|22nd December 2020||Barry J. Simon||130,000||Exercise of derivative||$2.00||$259,792.00|
|22nd December 2020||Barry J. Simon||130,000||Open or private sale||$18.05||$2,346,604.00|
|10th December 2020||John C Thomas||42,592||Open or private sale||$10.83||$461,122.29|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
NantKwest, Inc. engages in the development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.